每年冬季,RSV病毒威胁全球儿童健康,曾因疫苗研发失误致2名幼儿死亡,让该领域停滞半个世纪。如今智飞生物鼻喷RSV疫苗获临床试验受理,采用黑猩猩腺病毒载体技术,直击病毒入侵路径,有望为婴幼儿筑起防护盾。
参考文献:
智飞生物. 关于鼻喷重组呼吸道合胞病毒疫苗临床试验申请获得受理的公告. 2026-08-10. 受理号CXSL2600844.
Polack FP et al. Fatal enhanced respiratory syncytial virus disease in toddlers. Science Translational Medicine. PMC10712289. pmc.ncbi.nlm.nih.gov
Huang L et al. Protective immunity induced by intranasally inoculated serotype 63 chimpanzee adenovirus vector expressing RSV prefusion F glycoprotein in BALB/c mice. Frontiers in Microbiology. 2022. www.frontiersin.org
Dicks MDJ et al. A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence. PLoS ONE. 2012. journals.plos.org
WHO. Respiratory syncytial virus (RSV) disease burden data. www.who.int

